Cetera Advisors LLC Arcus Biosciences, Inc. Transaction History

Cetera Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$16.97 - $22.03 $11,386 - $14,782	-671 Reduced 5.65%	11,212 $227,000
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $22,503 - $32,641	1,410 Added 13.46%	11,883 $216,000
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $206,318 - $373,990	10,473 New	10,473 $216,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.